LM302: This phase I/II trial is evaluating how safe and tolerable a new targeted therapy (LM-302) is when combined with immunotherapy (toripalimab) in people with advanced solid cancersA Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Summary

This study has two phases: Dose Escalation and Dose Expansion. The Dose Escalation phase has two parts: Part 1a and Part 1b. In Dose Escalation Part 1a, participants will receive LM-302 as monotherapy in escalating doses using an accelerated titration combined with traditional 3+3 design. LM-302 is given via intravenous infusion (IV) on day 1 every 3 weeks. In Dose Escalation Part 1b, participants will receive LM-302 in escalating doses (via IV on Day 1 every 3 weeks) in combination with a fixed dose of Toripalimab (given via IV on Day 1 every 3 weeks). In the Dose Expansion phase, the study investigators will select appropriate dose(s) and/or cancer types.